XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Equity-based compensation (Tables)
6 Months Ended
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Summary of stock based compensation expense

During the three and six months ended June 30, 2022 and 2021, respectively, equity-based compensation expenses were as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

​

​

2022

​

2021

    

2022

    

2021

General and administrative value appreciation right awards

​

$

5,847

​

$

12,247

​

$

(4,906)

​

$

25,468

Research and development value appreciation right awards

​

​

—

​

​

549

​

​

—

​

​

1,092

General and administrative stock options

​

​

157,720

​

​

36,637

​

​

493,499

​

​

81,388

Research and development stock options

​

​

51,009

​

​

—

​

​

94,266

​

​

—

General and administrative restricted stock units

​

​

69,350

​

​

​

​

​

69,350

​

​

​

​

​

$

283,926

​

$

49,433

​

$

652,209

​

$

107,948

Summary of VARs issued and outstanding

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

​

​

    

Weighted

​

​

​

​

​

​

​

​

​

​

Average

​

​

​

​

Weighted

​

​

​

​

Remaining

​

​

​

​

Average

​

Total Intrinsic

​

Contractual Life

​

​

Number of Units

​

Exercise Price 

​

Value

​

(in years)

Outstanding as of December 31, 2021

 

359,487

​

$

0.01

​

$

136,038

​

7.6

Exercised

​

(79,326)

​

$

0.01

​

​

​

​

-

Forfeited

​

(52,884)

​

$

0.01

​

​

​

​

-

Outstanding as of June 30, 2022

​

227,277

​

$

0.01

​

$

69,319

​

7.0

​

​

​

​

​

​

​

​

​

​

​

Value appreciation right awards vested and exercisable at June 30, 2022

​

101,991

​

$

0.01

​

$

31,107

​

7.3

Summary of stock options outstanding

The following is a summary of the options outstanding as of June 30, 2022:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

​

​

​

Average

​

​

​

​

​

Shares

​

Weighted

​

Remaining

​

Aggregate

​

​

Underlying

​

Average

​

Contractual

​

Intrinsic

​

    

Options

    

Exercise Price

    

 Term (Years)

    

Value

Outstanding at December 31, 2021

​

2,696,473

​

$

1.09

​

9.6

​

​

—

Granted

​

1,704,000

​

​

0.31

​

​

​

​

​

Forfeited

​

(38,833)

​

​

2.87

​

-

​

​

​

Outstanding at June 30, 2022

 

4,361,640

​

$

0.77

 

9.4

​

$

13,632

​

​

​

​

​

​

​

​

​

​

​

Exercisable at June 30, 2022

​

574,738

​

$

1.24

​

9.0

​

$

—

Summary of valuation assumptions were used to calculate the estimated fair value of awards granted

The following was used in determining the fair value of stock options granted during the three and six months ended      June 30, 2021:

​

​

​

​

​

Three and

​

    

Six Months Ended

​

​

June 30, 

​

​

2022

Expected life

 

5-7 years

Expected volatility

 

73.50%

Risk-free interest rate

 

2.79% -2.83%

Expected dividend yield

 

—

Stock options and warrants  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Summary of stock options outstanding

As part of the Merger, the Company assumed the following legacy stock options and warrants:

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted

    

​

​

​

​

Shares

​

​

​

​

Average

​

​

​

​

​

Underlying

​

Weighted

​

Remaining

​

Aggregate

​

​

Options and

​

Average

​

Contractual

​

Intrinsic

​

​

Warrants

​

Exercise Price

​

 Term (Years)

​

Value

Legacy BioPharmX options - June 30, 2022

 

15,781

​

$

75.27

 

0.9

​

$

—

​

​

​

​

​

​

​

​

​

​

​

Legacy BioPharmX warrants - December 31, 2021

 

213,992

​

$

87.21

 

1.8

​

$

—

Expired

 

(2,222)

​

$

225.00

 

—

​

​

—

Legacy BioPharmX warrants - June 30, 2022

 

211,770

​

$

85.77

 

1.3

​

$

—

Restricted Stock Units  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Summary of stock options outstanding

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

​

​

    

Weighted

    

​

​

​

​

Shares

​

​

​

​

Average

​

​

​

​

​

Underlying

​

​

​

Remaining

​

Aggregate

​

​

Restricted

​

Grant Date

​

Contractual

​

Intrinsic

​

​

Stock Units

​

Fair Value

​

 Term (Years)

​

Value

Outstanding at December 31, 2021

 

—

​

$

—

 

—

​

$

—

Granted

​

450,000

​

$

0.31

​

1.0

​

​

139,500

Vested

 

(74,998)

​

$

0.31

 

—

​

$

—

Unvested at June 30, 2022

 

375,002

​

$

0.31

 

0.8

​

$

116,251

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​